Increasing incidence of linezolid-intermediate or -resistant, vancomycin-resistant Enterococcus faecium strains parallels increasing linezolid consumption

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2256-2259

  Scheetz, Marc H ^a,b   Knechtel, Stephanie A ^b   Malczynski, Michael ^b   Postelnick, Michael J ^b   Qi, Chao ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERIUM ISOLATE; DRUG USE; ENTEROCOCCUS FAECIUM; HUMAN; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR EPIDEMIOLOGY; NONHUMAN; PREDICTION; PRIORITY JOURNAL; TREND STUDY;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, BACTERIAL; ENTEROCOCCUS FAECIUM; EPIDEMIOLOGY, MOLECULAR; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; INCIDENCE; MUTATION; OXAZOLIDINONES; VANCOMYCIN RESISTANCE;

EID: 44449159275     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00070-08     Document Type: Article

References (16)

1. Facklam, R., and J. A. Elliott. 1995. Identification, classification, and clinical relevance of catalase-negative, gram-positive cocci, excluding the streptococci and enterococci. Clin. Microbiol. Rev. 8:479-495.
2. Herrero, I. A., N. C. Issa, and R. Patel. 2002. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium. N. Engl. J. Med. 346:867-869.
3. Jones, R. N., G. J. Moet, L. Woosley, H. S. Sader, and T. R. Fritsche. 2007. Critical evaluation of linezolid susceptibility testing using two automated systems (Vitek, Vitek2), abstr. D-225. Abstr. 47th Intersci. Conf. Antimicrob. Agents Chemother., Chicago, IL.
4. Kainer, M. A., R. A. Devasia, T. F. Jones, B. P. Simmons, K. Melton, S. Chow, J. Broyles, K. L. Moore, A. S. Craig, and W. Schaffner. 2007. Response to emerging infection leading to outbreak of linezolid resistant enterococci. Emerg. Infect. Dis. 13:1024-1030.
5. Lobritz, M., R. Hutton-Thomas, S. Marshall, and L. B. Rice. 2003. Recombination proficiency influences frequency and locus of mutational resistance to linezolid in Enterococcus faecalis. Antimicrob. Agents Chemother. 47:3318-3320.
6. Marshall, S. H., C. J. Donskey, R. Hutton-Thomas, R. A. Salata, and L. B. Rice. 2002. Gene dosage and linezolid resistance in Enterococcus faecium and Enterococcus faecalis. Antimicrob. Agents Chemother. 46:3334-3336.
7. Pai, M. P., K. A. Rodvold, P. C. Schreckenberger, R. D. Gonzales, J. M. Petrolatti, and J. P. Quinn. 2002. Risk factors associated with the development of infection with linezolid- and vancomycin-resistant Enterococcus faecium. Clin. Infect. Dis. 35:1269-1272.
8. Prystowsky, J., F. Siddiqui, J. Chosay, D. L. Shinabarger, J. Millichap, L. R. Peterson, and G. A. Noskin. 2001. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob. Agents Chemother. 45:2154-2156.
9. Qi, C., X. Zheng, A. Obias, M. H. Scheetz, M. Malczynski, and J. R. Warren. 2006. Comparison of testing methods for detection of decreased linezolid susceptibility due to G2576T mutation of the 23S rRNA gene in Enterococcus faecium and Enterococcus faecalis. J. Clin. Microbiol. 44:1098-1100.
10. Raad, I. I., H. A. Hanna, R. Y. Hachem, T. Dvorak, R. B. Arbuckle, G. Chaiban, and L. B. Rice. 2004. Clinical-use-associated decrease in susceptibility of vancomycin-resistant Enterococcus faecium to linezolid: a comparison with quinupristin-dalfopristin. Antimicrob. Agents Chemother. 48:3583-3585.
11. Ruggero, K. A., L. K. Schroeder, P. C. Schreckenberger, A. S. Mankin, and J. P. Quinn. 2003. Nosocomial superinfections due to linezolid-resistant Enterococcus faecalis: evidence for a gene dosage effect on linezolid MICs. Diagn. Microbiol. Infect. Dis. 47:511-513.
12. Scheetz, M. H., C. Qi, G. A. Noskin, J. R. Warren, M. J. Postelnick, M. Malczynski, J. Huang, and T. R. Zembower. 2006. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci. Diagn. Microbiol. Infect. Dis. 56:407-413.
13. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J. Clin. Microbiol. 33:2233-2239.
14. Tenover, F. C., P. P. Williams, S. Stocker, A. Thompson, L. A. Clark, B. Limbago, R. B. Carey, S. M. Poppe, D. Shinabarger, and J. E. McGowan, Jr. 2007. Accuracy of six antimicrobial susceptibility methods for testing linezolid against staphylococci and enterococci. J. Clin. Microbiol. 45:2917-2922.
15. Werner, G., M. Bartel, N. Wellinghausen, A. Essig, I. Klare, W. Witte, and S. Poppert. 2007. Detection of mutations conferring resistance to linezolid in Enterococcus spp. by fluorescence in situ hybridization. J. Clin. Microbiol. 45:3421-3423.
16. World Health Organization Collaborating Centre for Drug Statistics Methodology. 2007. Anatomic therapeutic chemical/defined daily dose (ATC/DDD) index. www.whocc.no/atcddd/. Accessed 4 November 2007.